Provexis (PXS) AI Stock Analysis

• Market Cap: £29.32M
• Dividend Yield: N/A
• Average Volume (3M): 426.62K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.18
• Revenue Growth: 61.13%
• EPS Growth: 33.33%
• Country: UK
• Employees: 2
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): N/A
• Shares Outstanding: 2,345,891,400
• 10 Day Avg. Volume: 0
• 30 Day Avg. Volume: 426,617
• PEG Ratio: 0.68
• Price to Book (P/B): 7.92
• Price to Sales (P/S): 7.95
• P/FCF Ratio: -30.33
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 48 Neutral
• Price Target: 1.00p ▲(40.85% Upside)
• Action: Reiterated Date: 02/11/26
• Date: Action: Reiterated 02/11/26

The score is held back primarily by weak financial performance (ongoing losses and cash burn), partially offset by a debt-free balance sheet and strong recent revenue acceleration. Technicals are supportive due to the strong uptrend, but overbought signals raise pullback risk. Valuation remains challenged because the company is still loss-making and does not offer a dividend yield.

Positive Factors

Debt-free balance sheet

A zero-debt capital structure materially reduces refinancing and interest-rate risk, giving management optionality to fund commercialization or R&D without immediate borrowing. Over 2-6 months this supports stability and negotiating leverage with partners, though scale and profitability still matter for long-term funding.

Rapid revenue acceleration

Sharp top-line acceleration signals improving commercial traction for Fruitflow® and stronger partner adoption. If sustained, accelerating revenue can spread fixed costs, improve gross margins, and enable reinvestment into sales/distribution. The durability depends on partner execution and continued product rollouts.

Specialised B2B ingredient model

A focused, science-backed ingredient sold B2B offers structural advantages: easier scalability, recurring ingredient revenues, and differentiation via clinical support. This model limits capital intensity versus manufacturing consumer brands and can generate licensing-like margins as adoption broadens across supplement and functional food partners.

Negative Factors

Persistent losses and weak margins

Deep negative operating and net margins reflect cost structure and limited profitability scale. Sustained losses erode retained earnings and constrain the firm's ability to self-fund growth or marketing to partners. Without clear margin expansion tied to higher volumes or pricing, profitability risk remains material over the medium term.

Negative operating and free cash flow

Consistent cash burn increases reliance on external financing and heightens dilution or funding risk. Even with improvements from prior years, negative OCF/FCF limits capacity to invest in commercialization, regulatory work, or partnerships without raises. Funding uncertainty is a material structural constraint for scaling.

Very small operational scale

Extremely small headcount and modest equity indicate limited internal resources to execute large-scale partner rollouts or broaden product offerings. Small scale raises execution risk, dependence on external partners, and sensitivity to single contract dynamics, challenging durable expansion without material investment.

Provexis Business Overview & Revenue Model

Company Description

Provexis plc, together with its subsidiaries, develops, licenses, and markets functional foods, medical foods, and dietary supplements worldwide. Its products include Fruitflow, a tomato extract that reduces the propensity for aberrant blood clotting typically associated with cardiovascular diseases, such as heart attack and stroke. The company's syrup and powder versions of Fruitflow are used in foods, beverages, and dietary supplement formats. It also offers Fruitflow + Omega-3, a supplement in capsule form that supports healthy blood flow and normal heart function. Provexis plc has a collaboration agreement with By-Health Co., Ltd. The company offers its products through retail stores, as well as online. Provexis plc was founded in 1999 and is based in Reading, the United Kingdom.

How the Company Makes Money

Provexis makes money primarily through the commercialization of its Fruitflow technology. The company generates revenue by licensing Fruitflow to manufacturers and distributors in the food and dietary supplement industries, allowing them to incorporate the ingredient into their products. Additionally, Provexis engages in collaborative partnerships and agreements with other companies to co-develop and market new products that incorporate its proprietary technology. These partnerships often involve upfront payments, milestone payments, and royalties based on product sales. The company's focus on intellectual property and innovation ensures a recurring revenue stream through licensing deals and collaborative ventures.

Provexis Financial Statement Overview

Summary

Revenue growth is accelerating sharply, but results remain dominated by persistent operating/net losses and ongoing negative operating/free cash flow. The balance sheet is a positive (no debt, positive equity), yet weak profitability and cash burn keep overall financial quality below average.

Income Statement

Revenue growth is improving, accelerating from roughly 106% (FY2024) to about 771% (FY2025), indicating better commercial traction off a small base. However, profitability remains weak: the company is still loss-making with negative operating profit and net income in every year provided, and FY2024 margins were deeply negative (net margin about -73% and operating margin about -75%). Overall, the top-line trend is a positive, but losses and poor margin structure keep the income statement score low.

Balance Sheet

The balance sheet is conservatively financed with zero total debt across all reported years, reducing refinancing and interest-rate risk. Equity is positive (about 1.30M in FY2025) and has improved versus FY2024, but returns remain negative (FY2024 return on equity around -81%), reflecting ongoing losses and limiting the quality of equity. Overall, the lack of leverage is a key strength, offset by weak profitability and smaller scale.

Cash Flow

Cash generation remains a key concern: operating cash flow and free cash flow are negative in every year shown (FY2025 operating/free cash flow about -339k). While free cash outflow improved materially versus FY2023 (as reflected in the strong free cash flow growth figure), the business is still consuming cash, which raises funding risk if losses persist. Overall, improving trend but still structurally negative cash flow.

Breakdown	Sep 2024	Mar 2023	Sep 2022	Sep 2021	Sep 2020
Income Statement
Total Revenue	1.29M	801.96K	389.92K	426.17K	505.33K
Gross Profit	532.94K	283.80K	294.42K	380.05K	456.19K
EBITDA	-449.63K	-603.59K	0.00	0.00	0.00
Net Income	-452.72K	-586.24K	-385.24K	-224.25K	-341.01K
Balance Sheet
Total Assets	1.01M	498.04K	845.99K	1.13M	1.29M
Cash, Cash Equivalents and Short-Term Investments	708.09K	189.36K	379.12K	863.87K	1.08M
Total Debt	0.00	0.00	0.00	0.00	0.00
Total Liabilities	248.21K	307.45K	188.34K	157.91K	150.68K
Stockholders Equity	1.30M	724.34K	1.19M	1.50M	1.66M
Cash Flow
Free Cash Flow	-338.90K	-191.50K	-519.85K	-213.79K	-262.32K
Operating Cash Flow	-338.90K	-191.50K	-519.85K	-213.54K	-262.07K
Investing Cash Flow	1.93K	1.73K	887.00	78.00	-250.00
Financing Cash Flow	857.63K	0.00	35.10K	1.05M	1.05M

Provexis Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.71
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:PXS, the sentiment is Neutral. The current price of 0.71 is below the 20-day moving average (MA) of 1.40, below the 50-day MA of 1.15, and below the 200-day MA of 0.78, indicating a neutral trend. The MACD of 0.06 indicates Positive momentum. The RSI at 48.82 is Neutral, neither overbought nor oversold. The STOCH value of 32.99 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for GB:PXS.

Provexis Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
EAH	76 Outperform	£65.39M	-44.80	3.62%	―	1.44%	359.79%
STX	63 Neutral	£96.59M	-1.10	-396.71%	―	93.48%	51.18%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
PXS	48 Neutral	£29.32M	-11.67	-51.21%	―	61.13%	33.33%
N4P	42 Neutral	£4.37M	-1.08	-73.08%	―	―	―
CHLL	41 Neutral	£2.88M	-1.61	―	―	―	―

Provexis Corporate Events

Provexis Hit by Interim Sales Dip as Supply Delay Masks Expanding Fruitflow Pipeline

Provexis reported unaudited interim revenue of £364,000 for the six months to 30 September 2025, sharply lower than the prior year due to a third‑party delay in a new production run of its Fruitflow II SD ingredient, which temporarily constrained sales in August and September. Despite the short-term impact, the company has since sold out its legacy DSM-sourced inventory, booked and/or taken orders worth several hundred thousand pounds for Fruitflow II SD after the period end, and is planning at least three new production runs over the next 12 months, while continuing to deepen its commercial ties with dsm-firmenich and support BYHEALTH’s large-scale, regulatory-driven launch plans in China that could significantly expand Fruitflow’s global footprint and enhance Provexis’s long-term growth prospects.

The most recent analyst rating on (GB:PXS) stock is a Hold with a £0.82 price target. To see the full list of analyst forecasts on Provexis stock, see the GB:PXS Stock Forecast page.